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In animal models, resident memory CD8þ T (Trm) cells assist in respiratory virus
elimination but their importance in man has not been determined. Here, using experimental
human respiratory syncytial virus (RSV) infection, we investigate systemic and local
virus-speciﬁc CD8þ T-cell responses in adult volunteers. Having deﬁned the immuno-
dominance hierarchy, we analyse phenotype and function longitudinally in blood and by serial
bronchoscopy. Despite rapid clinical recovery, we note surprisingly extensive lower airway
inﬂammation with persistent viral antigen and cellular inﬁltrates. Pulmonary virus-speciﬁc
CD8þ T cells display a CD69þCD103þ Trm phenotype and accumulate to strikingly high
frequencies into convalescence without continued proliferation. While these have a more
highly differentiated phenotype, they express fewer cytotoxicity markers than in blood.
Nevertheless, their abundance before infection correlates with reduced symptoms and viral
load, implying that CD8þ Trm cells in the human lung can confer protection against severe
respiratory viral disease when humoral immunity is overcome.
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C
D8þ T cells are essential effectors that eliminate
intracellular pathogens and confer protection against
symptomatic reinfection via immune memory1.
In animal models of respiratory virus infections such as
respiratory syncytial virus (RSV) and inﬂuenza, memory
CD8þ T cells reduce viral replication, prevent infection or
decrease disease severity, and confer cross-protection against
antigenically distinct strains2. However, while some vaccine
candidates against RSV and inﬂuenza may have the capacity to
induce CD8þ T cells, they have not yet been shown clinically to
improve protection3–5.
RSV is globally the commonest cause of lower respiratory tract
infection in children, leading to an estimated 3.4 million
hospitalizations each year6. It is also a major contributor to
mortality in older and immunosuppressed adults7. Recurrent
symptomatic RSV infection occurs throughout life even with a
healthy immune system and limited viral antigenic variation8.
Therefore, characterizing immune responses required for robust
protection has been problematic and effective vaccines remain a
major clinical need2. We recently showed that anti-RSV IgA in
the nasal mucosa correlated strongly with protection from
infection, but that the high levels required for immunity are
poorly maintained, allowing recurrent infection9. Despite this,
most older children and young adults suffer only minor
symptoms, implying that when antibodies fail to prevent
infection, cell-mediated immunity reduces disease severity.
In mice, depletion of RSV-speciﬁc CD8þ T cells leads
to prolonged viral replication, while adoptive transfer of
virus-speciﬁc memory cells enhances virus clearance10,11.
However, the absence of T cells also leads to reduced symptom
severity and transfer of RSV-speciﬁc memory T cells worsens
disease, indicating that harmful immunopathology can outweigh
the beneﬁts of cell-mediated viral clearance under certain
circumstances12,13. In humans, the role of CD8þ T cells
remains less clear with evidence of their protective role mainly
limited to observations of children with T-cell defects (who suffer
more severe disease with prolonged viral shedding)14. In
inﬂuenza, correlations between memory T cells in the blood
and reduced severity of disease on subsequent infection have been
shown15,16, but no such evidence exists in RSV and the extent to
which T cells contribute to protection or pathology in this and
other respiratory viral infections remains unknown.
Respiratory viruses are usually conﬁned to the lung with
systemic spread only in the worst cases17. Virus-speciﬁc CD8þ T
cells in peripheral blood are therefore unlikely in most situations
to be directly relevant to protection. Instead, studies of a range of
tissues have recently deﬁned a subset of non-circulating memory
T cells specialized to protect sites of pathogen entry18. These
resident memory T (Trm) cells are not only poised for rapid
killing on virus re-encounter but may also exhibit innate-like
sensing functions19. In mouse models of inﬂuenza, CD4þ and
CD8þ Trm cells in the lung confer greater protection than
spleen-derived cells20,21. However, restrictions on sampling of
human lungs mean that little is known about these Trm cells
except that they are abundant in non-inﬂamed lung from tumour
excisions or donated organ tissue22,23.
We investigated the CD8þ T-cell response to experimental
RSV infection in 49 healthy adult volunteers, around half of who
also underwent serial bronchoscopy. While controlled for
variations in viral inoculum and co-morbidities, this cohort
nevertheless represented a genotypically diverse antigen-
experienced population that allowed characterization of the
breadth of virus-speciﬁc CD8þ T-cell responses and identi-
ﬁcation of novel immunodominant and subdominant epitopes.
Analysis using major histocompatibility complex (MHC)-peptide
tetramers revealed highly contrasted kinetics, phenotypes and
functionality of RSV-speciﬁc CD8þ T cells in the lower
respiratory tract compared with blood, the diversity of which
allowed us to infer a specialised role in protection against RSV
disease.
Results
Experimental RSV infection causes upper tract disease. We
enrolled 49 healthy adults aged 18–50 years (median 20.5 years;
Supplementary Table 1). Two weeks and immediately before
inoculation, they underwent blood and nasal sampling (Fig. 1a).
All individuals were then inoculated with 104 plaque-forming
units of RSV A Memphis 37 (RSV M37) by intranasal drops as
previously described9, followed by sequential blood and nasal
samples up to 6 months later.
Twenty-six subjects (53%) developed PCRþ infection
(Fig. 1b). Of these, 17 (65%) suffered a ‘common cold’ according
to standardized criteria (see Methods), while 9 (35%) reported
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Figure 1 | Inoculation of healthy adults with RSV causes upper respiratory tract infection. Forty-nine healthy adult volunteers were inoculated with RSV
Memphis 37. (a) The study design is shown. (b) Clinical outcomes are shown. (c) Self-reported symptoms scores of 49 subjects were recorded daily.
Cumulative data are shown as mean±s.e.m. Infected individuals were deﬁned by having had RSVdetected from nasal lavage on at least 2 consecutive days
by qPCR of nasal lavage. (d) Symptoms from 49 subjects were categorized as originating from the upper respiratory tract (blue), lower respiratory tract
(red) or as systemic (green) according to previously described criteria (see Methods). Data are shown as mean± s.e.m. (e) Viral load of 49 individuals
was determined by N gene qPCR from nasal lavage. Individual data points and means are shown.
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minimal or no symptoms. Symptoms in infected individuals
peaked around day 7 post inoculation (Fig. 1c). While almost all
symptomatic individuals complained of upper respiratory
symptoms, lower respiratory tract and systemic symptoms were
unusual (Fig. 1d). In infected individuals, viral load peaked at
days 7–8 post infection with a mean of 2.76 log10 copies per ml
(±s.e.m. 0.322; Fig. 1e), correlating with self-reported symptoms
(Supplementary Fig. 1).
RSV causes inﬂammation in the lower respiratory tract.
Twenty-four volunteers additionally underwent serial broncho-
scopy (Supplementary Table 2). Thus, endobronchial biopsies,
bronchial brushings and bronchoalveolar lavage (BAL) were
obtained 14 days before inoculation and 7 or 10 and 28 days after.
Of these, 50% developed RSV infection. In view of the
predominantly upper respiratory disease, we were surprised to
ﬁnd strikingly extensive macroscopic inﬂammation involving the
lower respiratory tract of infected individuals (Fig. 2a;
Supplementary Table 3). Lower airways involvement was sup-
ported by quantitative PCR (qPCR) of bronchial brushings, which
detected RSV in all day 7 samples and 4/5 infected subjects at day
10, again peaking around 7 days (mean 2.22 log10ml 1±s.e.m.
0.416; Fig. 2b). RSV could also be measured in BAL in 5/7
individuals at day 7 at lower copy numbers (peak 1.48
log10ml 1±s.e.m. 0.412). Interestingly, virus was detected
in bronchial brushings of an additional four subjects in whom
no virus was found in nasal lavage. These were found at
low-to-moderate copy numbers (0.31 log10ml 1 at day 7, and
0.69, 0.17 and 1.76 log10ml 1 at day 10) and were reproducible
on repeat assay.
To conﬁrm the unexpected presence of RSV in the lower
airway, endobronchial biopsies were analysed by immunohisto-
chemistry (Fig. 2c). While RSV antigen was not found
pre-inoculation, all individuals with PCR-detectable virus in the
nose had at least moderate antigen staining at both acute and
convalescent time points. Of these, 3/11 had extensive RSV
antigen in bronchial biopsies at day 7–10 and 3/10 at day 28
(Supplementary Table 4). In contrast, PCR subjects had, at
most, staining of isolated epithelial cells, suggesting the presence
of RSV antigen but no onward spread. RSV antigen was
associated with inﬁltration of CD8þ T cells (Fig. 2d). In those
with PCRþ bronchial brushings, CD8þ T cells increased
signiﬁcantly in both the epithelial and subepithelial layers at
acute and convalescent time points (Fig. 2e). In contrast,
while CD8þ T cells did increase transiently in the biopsies of
PCR individuals, these were less consistently seen and did not
remain signiﬁcantly elevated at day 28. Thus, experimental
infection of adults with RSV can lead to virus replication in the
lower airway, which causes marked inﬂammation associated with
inﬁltration of CD8þ T cells.
RSV viral load drives CD8þ T-cell proliferation. To further
investigate the kinetics of the response, CD8þ T cells induced by
RSV were tracked by ﬂow cytometry using markers of
proliferation (Ki-67) and activation (CD38; Fig. 3a). From day 7
post infection, activated CD8þ T cells in blood expanded
peaking around day 10 (mean 2.1%±s.e.m. 0.297 of CD8þ
lymphocytes), after which Ki-67þCD38þ CD8þ T cells
rapidly returned to baseline frequencies (Fig. 3b). No signiﬁcant
proliferative response was seen in PCR individuals,
indicating that antigen challenge without viral replication
was not sufﬁcient to induce CD8þ T-cell activation (Fig. 3c).
Similarly, frequencies of activated CD8þ T cells increased in
BAL (Fig. 3d). However, the average frequency was signiﬁcantly
higher than in blood (P¼ 0.0098 Wilcoxon matched pairs
test; Fig. 3e). The appearance of activated CD8þ T cells
coincided with the fall in viral load (Fig. 1e). Antigen availability
and inﬂammation both contribute to T-cell activation, and
indeed, cumulative viral load and symptoms (by trapezoidal area
under the curve) both correlated with the peak frequency of
activated CD8þ T cells (Fig. 3f,g), suggesting that increased virus
burden and/or inﬂammatory changes in the airway drive T-cell
activation, which in turn leads to viral clearance.
HLA-associated immunodominance hierarchies against RSV.
Antigenic targets of RSV-speciﬁc CD8þ T cells have not been
systematically investigated and only a few isolated epitopes have
been identiﬁed24,25. To deﬁne the breadth of these responses, we
generated a peptide library from RSV M37 predicted to bind the
most common human leukocyte antigen (HLA)-A and HLA-B
alleles using the Immune Epitope Database consensus prediction
tools26. The top 1% of predicted MHC-binding peptides for each
RSV protein was pooled and peptide pools used to screen peripheral
blood mononuclear cells (PBMCs) from subjects at day 10 post
infection by interferon-g (IFN-g) enzyme-linked immunospot
(ELISpot). Pools containing peptides from M, N, P, NS1 and NS2
(all internal proteins) induced IFN-g production (Fig. 4a).
Pools that stimulated responses were subsequently decon-
voluted to individual epitopes (Fig. 4b; Supplementary Table 5).
In the context of A*01:01, two epitopes (previously described
YLEKESIYY [YLE]25 and the novel VTDNKGAFKY [VTD]) that
elicited dominant responses were identiﬁed in the M protein and
one subdominant epitope (LSDSTMTNY [LSD]) in the NS1
protein (Supplementary Table 5). A 10-mer differing from LSD in
one additional amino acid also induced responses but had a 100-
fold lower MHC-binding afﬁnity. YLE and VTD were conserved
with the prototypic RSV A2 strain. Only a single A*02:01-restricted
epitope (FLVNYEMKL [FLV]) was identiﬁed, derived from the
NS2 and conserved with RSV A2. Finally, with B*07:02, four
epitopes were deﬁned: NPKASLLSL (NPK, described previously25)
and QVMLRWGVL (QVM) from N protein (previously shown as
part of a longer polypeptide to induce IFN-g in some individuals27);
IPAYRTTNY (IPA) from L; and KPNIRTTLL (KPN) from G (not
conserved with RSV A2). VTD, LSD and FLV have previously been
predicted but not conﬁrmed as epitopes on the basis of HLA-
binding afﬁnity alone28. Indeed, all but three epitopes exhibited
moderate to good measured MHC peptide-binding afﬁnity
(o500nM). Importantly, each HLA allele presented epitopes
from different RSV proteins with no overlap in the speciﬁcities of
CD8þ T cells targeted against them.
In subjects with sufﬁcient PBMCs, RSV-speciﬁc CD8þ T-cell
responses were analysed before, during and after infection using
IFN-g ELISpot. Before infection, epitope-speciﬁc cells were rare,
with a median (interquartile range (IQR)) of 45 (6–61)
spot-forming units (SFU) per million PBMCs (A*01:01); 28
(13–52) SFU per million PBMCs (B*07:02); and o5 (o5–11)
SFU per million PBMCs (A*02:01; Fig. 4c,d; Supplementary
Table 6). At the peak of the CD8þ T-cell response, these had
increased byB10-fold to 194 (114–452) SFU per million PBMCs
for A*01:01; 231 (138–577) SFU per million PBMCs for B*07:02;
and 28 (18–52) SFU per million PBMCs for A*02:01. The extent
of expansion between the three HLA-restricted responses was
similar (Fig. 4d; Supplementary Fig. 2). By day 28, these
populations had contracted but remained enlarged compared
with baseline in most individuals.
Throughout the course of infection, the immunodominance
hierarchy was maintained both between individuals and within
subjects who expressed two or three of these HLA alleles. Thus,
A*01:01-restricted responses were consistently greater than
those against B*07:02-restricted epitopes and those against the
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Figure 2 | RSV infection of healthy adults causes widespread lower respiratory tract inﬂammation. Twenty-four volunteers underwent serial
bronchoscopic procedures 14 days before inoculation with RSV M37, 7 or 10 days and 28 days post inoculation. (a) The macroscopic appearance of the
airways was noted by bronchoscopists blinded to the infection status of the subject. One representative subject is shown. (b) Viral load was determined
from bronchial brushings (solid line) and bronchoalveolar lavage (dashed line) by qPCR. Cumulative data are shown as mean±s.e.m. (c) RSV antigen
(brown) was detected in bronchial biopsies by immunohistochemistry. One representative donor is shown. (d) CD8þ cells (brown) were identiﬁed in
bronchial biopsies by immunohistochemistry. Scale bar, 20mm. (e) CD8þ cells were enumerated in bronchial biopsies of infected individuals (with RSV
detected by qPCR in bronchial brushings) and PCR individuals. Data are presented as number of positive cells per square millimetre of subepithelium or
per 0.1mm2 of epithelium. Signiﬁcant P values for two-tailed Wilcoxon matched pairs tests are shown (*Po0.05, **Po0.01, ***Po0.001) comparing (with
baseline) epithelial PCRþ samples at day 7–10 (P¼0.0012) and day 28 (P¼0.004), epithelial PCR samples at day 7–10 (P¼0.0469), subepithelial
PCRþ samples at day 7–10 (P¼0.0004) and day 28 (P¼0.0419), and subepithelial PCR samples at day 7–10 (P¼0.0156).
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Figure 3 | RSV infection induces short-lived activation and proliferation of CD8þ T cells in peripheral blood. Forty-nine adult volunteers were
inoculated with RSVMemphis 37, serial blood (n¼49) and BAL (n¼ 24) samples were stained with anti-CD3, CD8, Ki-67 and CD38, and analysed by ﬂow
cytometry. (a) Plots are gated on CD3þCD8þ lymphocytes. Numbers represent percentage of CD8þ T cells. One representative subject is shown.
(b) Mean and s.e.m. of Ki-67þCD38þ CD8þ T-cell frequencies in the blood of infected (PCRþ ) and challenged but uninfected (PCR ) are shown. The
P value for a two-tailed Wilcoxon matched pairs test is shown (***Po0.001). (c) Frequencies of Ki-67þCD38þ cells as a proportion of CD8þ T
lymphocytes were determined at day 10 post inoculation in infected and uninfected individuals. Mean±s.e.m. are shown with the P -value for a two-tailed
Mann–Whitney test (***P¼0.001). (d) Mean and s.e.m. of Ki-67þCD38þ CD8þ T-cell frequencies in the BAL of infected (PCRþ ) and challenged but
uninfected (PCR ) are shown. The signiﬁcant P value for a two-tailed Wilcoxon matched pairs test is shown (*P¼0.0317). (e) Frequencies of
Ki-67þCD38þ cells, as a proportion of CD8þ T lymphocytes were determined at day 10 post inoculation in matched blood and BAL samples. The
signiﬁcant P value for the Wilcoxon matched pairs tests is shown (**P¼0.0059). Correlations between peak frequencies of Ki-67þCD38þ CD8þ Tcells
10 days post infection in blood and (f) cumulative viral load and (g) symptoms (trapezoidal area under the curve (AUC)) are shown using non-linear
regression and Spearman’s rank correlation.
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Figure 4 | Immunodominance hierarchies in MHC class-I-restricted RSV epitope-speciﬁc CD8þ T-cell responses. Epitopes were predicted in silico for
binding and used to stimulate day 10 PBMCs from HLA-matched infected volunteers with sufﬁcient cells (HLA A*01:01, n¼4; A*02:01, n¼ 5; and B*07:02,
n¼4) in interferon-g (IFN-g) ELISpot assays. (a) Peptides were pooled according to their originating RSV protein. Two-tailed Mann–Whitney tests were
carried out between peptide pools and negative control wells (A*01:01_NS1/N, P¼0.0286; A*02:01_NS1/N, P¼0.0079; A*02:01_NS2/P, P¼0.0119; and
B*07:02_NS1/N, P¼0.0286). (b) Individual peptides from positive pools were subsequently tested separately. Dotted lines represent a cutoff of 25 spots
per 106 PBMCs. Means±s.e.m. and P values for unpaired Mann–Whitney tests are shown (A*01:01_NS1_2, P¼0.0286; A*01:01_NS1_4, P¼0.0286;
A*01:01_M_2, P¼0.0294; A*01:01_M_7, P¼0.0294; A*02:02_NS2_3, P¼0.0002; B*07:02_N_2, P¼0.0079; B*07:02_N_8, P¼0.0079; B*07:02_G_2,
P¼0.0278; and B*07:02_L_3, P¼0.0079). (c) The median frequencies of IFN-gþ cells in response to individual RSV epitopes presented by HLA-A*01:01
(blues), A*02:01 (reds) and B*07:02 (greens) are shown in 17 HLA-matched RSV-infected individuals at day 0, 10 and 28 post infection. (d) The
frequencies of median total IFN-g-producing cells at baseline, day 10 and day 28 post infection in response to HLA-A*01:01 (blue)-, A*02:01 (red)- and
B*07:02 (green)-restricted epitopes in 17 HLA-matched infected individuals are shown. P values for Wilcoxon matched pairs tests are shown (A*01:01,
P¼0.0117; A*02:01, P¼0.0039; and B*07:02, P¼0.125; NS (not signiﬁcant)¼ P40.05, *Po0.05, **Po0.01, ***Po0.001).
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A*02:01-restricted FLV epitope were B10-fold lower. However,
the FLV response was more prominent in individuals without the
A*01:01 or B*07:02 alleles, suggesting the effect of immunodo-
mination. Thus, we identiﬁed several new RSV epitopes (both
immunodominant and subdominant) for three common HLA
alleles with potential as vaccine targets. The immunodominance
hierarchies indicated marked quantitative differences in responses
determined by HLA type and the inﬂuence of HLA alleles on each
other when co-expressed.
RSV-speciﬁc CD8þ T cells accumulate in convalescent airways.
MHC peptide tetramers were constructed using three immuno-
dominant epitopes (A1-M-YLE, A2-NS2-FLV and B7-N-NPK) to
investigate RSV-speciﬁc CD8þ T cells in further detail by ﬂow
cytometry in blood and BAL (Fig. 5a). In blood at baseline,
tetramerþ cells were found at low frequencies ranging from
undetectable to 0.03% of CD8þ lymphocytes (Fig. 5b,d). After
day 7 post infection, these expanded coincident with the fall in
viral load (Fig. 1e). They peaked at day 10 post infection with up
to a mean 18-fold increase, after which epitope-speciﬁc popula-
tions contracted rapidly. While tetramerþ cells still remained
elevated in most individuals 28 days post infection, their numbers
were not maintained long term, so that by 6 months post
infection there was no statistical difference compared with their
preinfection levels.
Analysis of matched BAL samples from the same infected
subjects, however, revealed an unexpected pattern of CD8þ
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shown: NS (not signiﬁcant)¼ P40.05, *Po0.05, **Po0.01. Mean±s.e.m. of epitope-speciﬁc CD8þ T-cell responses are shown in (d) blood (n¼ 20)
and (e) BAL (n¼ 13).
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T-cell kinetics that diverged markedly from those in blood
(Fig. 5c). While in this compartment, tetramerþ cells also started
increasing in frequency after 7 days, at both day 10 and day 28
they were signiﬁcantly more frequent than in blood (P¼ 0.0078
and 0.0002, respectively, Wilcoxon matched pairs test), with a
sevenfold higher mean frequency of A1-M-YLEþ cells in BAL
than in blood at day 10 (Fig. 5d,e). Furthermore, the frequency of
tetramerþ cells continued to rise in BAL into the convalescent
period despite the absence of symptoms or virus detection by
qPCR, while contraction of these populations had occurred in
blood. Therefore, at day 28 post infection, the mean frequency of
A1-M-YLEþ cells was 114-fold greater in BAL than in blood.
Phenotypically distinct RSV-speciﬁc CD8þ T cells in airways.
In view of the strikingly divergent kinetics in BAL and blood,
we went on to analyse the phenotypic differences between
RSV-speciﬁc CD8þ T cells in the two compartments. In BAL at
rest, almost all (80–90%) tetramerþ cells displayed the canonical
CD69þCD103þ Trm phenotype (Fig. 6a). In contrast, before
infection, no tetramerþ cells in blood expressed either marker.
However, during infection, a proportion of tetramerþ cells in
blood upregulated CD103, peaking at day 10 then decreasing with
resolution of infection. In BAL, the CD103 single-positive
population also increased in frequency at day 10, transiently
making up a greater proportion of tetramerþ cells, which then
returned to a predominantly CD69þCD103þ phenotype
during convalescence.
Analysis of CD45RA and CCR7 allowed further categorization
of memory subsets and indicated that the majority of tetramerþ
cells exhibited effector memory (Tem) or effector memory
re-expressing CD45RA (Temra) phenotypes, with predominantly
Tem cells in BAL (Fig. 6b). In blood, infection led to a signiﬁcant
increase in T-effector cells (expressing the CD45RA /CCR7þ
phenotype) at the expense of Temra cells, a change that was not
seen in the airway. This occurred via proliferation starting
between day 3 and day 7 post infection, paralleling the polyclonal
CD8þ T-cell response and peaking at around day 10, when
B85% (IQR 70–92%) of epitope-speciﬁc CD8þ T cells in blood
showed activation and proliferation by CD38 and Ki-67
expression (Fig. 6c). This was also seen in tetramerþ BAL cells,
although a proportion of these remained quiescent. However, by
day 28, despite the continued accumulation of tetramerþ cells in
the BAL, there was no evidence of on-going activation or
proliferation.
In blood, these cells upregulated perforin and granzyme B,
which also peaked around day 10 with around 33% (median, IQR
17–46%) expressing cytotoxicity molecules (Fig. 7a). However,
few tetramerþ BAL cells expressed perforin. Furthermore, only a
minority upregulated granzyme B, which again peaked around
day 10. During infection, the co-stimulatory molecules CD27 and
CD28 were both downregulated in a proportion of RSV-speciﬁc
CD8þ T cells in the blood and in the majority of individuals had
not returned to baseline frequencies by day 28 (Fig. 7b). In
contrast, even before infection, a large proportion of RSV-speciﬁc
CD8þ T cells had already downregulated CD28 and CD27þ
CD28þ double-positive cells were in the minority. Furthermore,
there were no signiﬁcant changes in their expression following
infection. Finally, following activation, RSV-speciﬁc CD8þ
T cells in blood upregulated CCR5 and downregulated CD62L,
allowing homing to sites of inﬂammation and away from
lymphoid tissues (Fig. 7c; Supplementary Fig. 3). In BAL, there
was a trend towards tetramerþ Trm cells upregulating CCR5
and there was no CD62L expression at any time.
These data suggest that RSV infection induces a transient
increase of virus-speciﬁc CD8þ T cells in the blood, with a
phenotype characteristic of cytotoxic effector cells, some of which
changes persist into the convalescent period. In contrast, Trm
cells in the airway alter less markedly following infection, with a
large proportion showing no proliferative response and overall
reduced expression of cytotoxicity molecules.
Limited functionality of RSV-speciﬁc CD8þ memory T cells.
In studies of inﬂuenza, virus-speciﬁc CD8þ memory T-cell
frequencies in the blood have been shown to correlate inversely
with symptom severity during subsequent infection15,16. This has
not been demonstrated with other viruses, and indeed we
found no signiﬁcant difference in baseline frequencies of
RSV-speciﬁc CD8þ T cells in peripheral blood between those
subsequently deemed infected and those who remained
uninfected (Supplementary Fig. 4a). In addition, there was no
statistical relationship between the magnitude of pre-existing
HLA-restricted responses and the severity of disease, expressed
throughout as cumulative viral load or symptom score to smooth
out day-to-day variability in spite of the close correlation between
peak and cumulative values (Supplementary Fig. 4b).
Analysis of CD8þ T cells induced by highly protective
systemic vaccines, such as yellow fever, have displayed poly-
functionality that may correlate with their efﬁcacy29.
To investigate whether the functionality of RSV-speciﬁc CD8þ
T cells might be contributing to lack of protection, cytokine
production was analysed by ﬂow cytometry (Fig. 8a). Overall,
the frequencies of cytokine-producing CD8þ T cells following
short-term peptide stimulation were modest with average median
frequencies of 0.035 (against YLE) and 0.056% (against NPK).
These were similar to those seen against the immunodominant
inﬂuenza epitope M1-GIL in A*02:01-expressing individuals from
this cohort. However, most cytokine-expressing RSV-speciﬁc cells
produced only a single cytokine (IFN-g, tumour necrosis factor or
interleukin-2) with an average of only 2.63% (±s.e.m. 0.432)
producing three (Fig. 8b,c; Supplementary Fig. 5). By comparison,
inﬂuenza-speciﬁc CD8þ T cells were more polyfunctional, with
39% producing two cytokines and a signiﬁcantly higher
proportion (15.1%±s.e.m. 2.30) producing three (P¼ 0.0079
by Mann–Whitney test). Thus, RSV-speciﬁc memory CD8þ
T cells in blood have reduced functionality compared with those
against inﬂuenza, potentially contributing to reduced protective
capacity.
CD8þ Trm cells in airways correlate with reduced disease.
These ﬁndings mirror our previous study that showed
RSV-speciﬁc nasal IgA correlating strongly with protection from
PCR-conﬁrmed infection with greater predictive power than
serum IgG in this regard9. However, where infection did
occur, high nasal IgA titres did not reduce disease severity
(Supplementary Fig. 6). We hypothesized that local cell-mediated
immunity could provide the next layer of defence by acting to
directly eliminate cell-associated virus and thus reduce
symptoms. To test this, we analysed the frequencies of
tetramerþ CD8þ T cells against immunodominant epitopes
(representative of the RSV-speciﬁc CD8þ T-cell population
before infection) and their relationship with infection risk and
disease severity. At baseline, RSV-speciﬁc CD8þ Trm cells were
already enriched in BAL with signiﬁcantly higher frequencies
compared with blood irrespective of speciﬁcity (Fig. 9a).
However, in contrast to mucosal IgA, their frequency had no
impact on the likelihood of PCR-conﬁrmed RSV infection
(Fig. 9b). Instead, the higher the frequency of RSV-speciﬁc
CD8þ T cells in baseline BAL, the lower the cumulative
symptom score (Spearman’s r¼  0.691, P¼ 0.0142; Fig. 9c) and
the lower the cumulative viral load (Spearman’s r¼  0.668,
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Figure 6 | RSV-speciﬁc CD8þ T cells in BAL display a distinctive resident memory phenotype. Tetramerþ CD8þ T cells in blood and BAL were co-
stained for markers to assess their differentiation status. (a) CD69 and CD103 as canonical markers of resident memory CD8þ Tcells are shown in blood
(n¼9) and BAL (n¼ 5) from infected volunteers. Signiﬁcant P values for two-tailed Wilcoxon matched pairs tests in blood compared with baseline are
shown (day 7, P¼0.0313; day 10, P¼0.0039; day 14, P¼0.0313; and day 28, P¼0.0313). (b) Memory markers CD45RA and CCR7 are shown in blood
(n¼ 19) and BAL (n¼8). Mean±signiﬁcant P values for two-tailed Wilcoxon matched pairs tests compared with baseline are shown in blood for
T-effector/effector memory cells (day 7, P¼0.0034; day 10, P¼0.0002; day 14, P¼0.0002; day 28, P¼0.0067) and effector memory T cells
re-expressing CD45RA (day 7, P¼0.0443; day 10, P¼0.0025; day 14, P¼0.0003; day 28, P¼0.0135). (c) Proliferation and activation markers Ki-67 and
CD38 are shown in blood (n¼ 19) and BAL (n¼8). Signiﬁcant P values for two-tailed Wilcoxon matched pairs tests are shown compared with baseline in
blood (day 7, P¼0.0025; day 10, P¼0.0001; and day 14, P¼0.0005) and BAL (day 7 versus day 10, P¼0.0444; and day 10 versus day 28, P¼0.0022
as no Ki-67þCD38þ cells were found in any baseline samples). Throughout, representative plots from a single subject at day 0, 10 and 28 post infection
are shown with tetramerþ cells as red dots and total CD8þ Tcells in grey contours. Summarized data are shown for all RSV-infected subjects (who could
be analysed using tetramers) with median frequencies shown in red. Abbreviated P values are shown: NS (not signiﬁcant)¼ P40.05, *Po0.05, **Po0.01.
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Figure 7 | Reduced expression of cytotoxicity and co-stimulatory markers by RSV-speciﬁc CD8þ T cells in the airway. Tetramerþ CD8þ T cells in
blood and BAL were co-stained for phenotypic markers. (a) Cytotoxicity molecules perforin and granzyme B are shown in blood (n¼ 19) and BAL (n¼ 5).
Signiﬁcant P values for two-tailed Wilcoxon matched pairs tests compared with baseline are shown in blood (day 7, P¼0.0144; day 10, P¼0.0009; and
day 14, P¼0.0413). (b) Co-stimulatory molecules CD27 and CD28 are shown in blood (n¼ 19) and BAL (n¼ 10). Mean±s.e.m. and signiﬁcant P values for
two-tailed Wilcoxon matched pairs tests compared with baseline are shown in blood for CD27þCD28þ cells (day 14, P¼0.0454; day 28, P¼0.0068)
and CD27CD28 cells (day 28, P¼0.0144). (c) Homing receptors CCR5 and CD62L are shown in blood (n¼ 19) and BAL (n¼ 5). Signiﬁcant P values
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representative plots from a single subject at day 0, 10 and 28 post infection are shown with tetramerþ cells as red dots and total CD8þ T cells in grey
contours. Summarized data are shown for all RSV-infected subjects (who could be analysed using tetramers) with median frequencies shown in red.
Abbreviated P values are shown: NS (not signiﬁcant)¼ P40.05, *Po0.05, **Po0.01.
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P¼ 0.0317; Fig. 9d) in those who subsequently developed PCRþ
infection. These correlations held true on correlation with lower
respiratory tract symptoms alone (Fig. 9e, Spearman’s r¼ 0.634,
P¼ 0.02) but less so with upper tract or systemic symptoms
(Supplementary Fig. 7). Similarly, higher frequencies of
pre-existing CD8þ Trm cells correlated with lower bronchial
viral load (Spearman’s r¼ 0.57, P¼ 0.042; Fig. 9f), suggesting that
these cells might have a direct role in viral clearance. In summary,
while memory CD8þ T cells in blood do not correlate with
protection against RSV, higher frequencies of CD8þ Trm cells in
the airway are associated with improved viral control and reduced
symptom severity, suggesting that these are likely to have a role in
ameliorating disease if present in sufﬁciently high numbers.
Discussion
Studies in animal models have increasingly highlighted the
distinctiveness of local immunity and the importance of this
compartmentalization to protective immune responses. Here we
present the ﬁrst interventional study to track virus-speciﬁc
cell-mediated immunity in the human airway. Longitudinal analysis
of the CD8þ T-cell response showed the extent to which these
cells in the human airway diverge from those in the blood during
RSV infection in almost every respect and provides strong evidence
for the role that human Trm cells play in protection.
RSV caused surprisingly extensive inﬂammation in most
infected individuals despite minimal or no lower respiratory
tract symptoms. Compared with rhinovirus (where neither
macroscopic inﬂammation nor cellular inﬁltrates are signiﬁcantly
seen on bronchoscopy in healthy adults30), RSV led to
substantially greater lower respiratory tract involvement.
Infection caused CD8þ T-cell inﬁltration of the respiratory
mucosa with an unexpected accumulation of very large numbers
of RSV-speciﬁc cells well into convalescence, distinct from blood
in the same individuals. In both blood and airway, activation of
CD8þ T cells occurred acutely, coinciding with falling viral load,
suggesting their involvement in virus elimination. Shortly after
peak viral shedding, proliferation ceased, implying that viral
replication was required to drive this response.
In immunodeﬁcient children, the absence of T cells is associated
with prolonged and more severe infection, while RSV disease risk in
older adults is believed to be related to fewer IFN-g-producing T
cells14,31. However, the low frequency, short-lived boosting and
possibly limited functionality of RSV-speciﬁc memory CD8þ T
cells in blood meant that poor correlation with protection was seen.
In contrast, epitope-speciﬁc CD8þ Trm cells in the airways with
their signiﬁcantly higher frequencies and localization near the site of
infection did indeed correlate with reduced disease severity. This
strongly supports the hypothesis that virus-speciﬁc CD8þ Trm
cells in the airway play a direct role in early clearance of respiratory
viruses, while memory T cells in blood correlate indirectly (if at all).
Previous studies in man, including those inferring the protective
role of CD4þ and CD8þ T cells from peripheral blood in
inﬂuenza15,16, make the assumption that there is a direct and
proportional relationship between blood and mucosal immunity.
Our ﬁndings show that this assumption is fundamentally incorrect
and that these compartmentalized populations must be examined
directly. Recent phase-I clinical trials have shown that virus-
vectored RSV vaccine candidates can induce T cells in blood32. Our
data suggest that their capacity to induce Trm cells following
intranasal administration should be explored further. These
ﬁndings might also explain why CD8þ T-cell-inducing inﬂuenza
vaccines that induce primarily systemic responses demonstrate
suboptimal efﬁcacy5,33.
In mice, expression of the receptors CD69 and CD103 allows
retention of CD8þ Trm in tissues34. Although they may not
represent the entire Trm population35, CD69þCD103þ CD8þ
Trm cells have been shown to localize to the murine airway
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following respiratory priming with inﬂuenza and mediate
cross-protection against heterologous strains21. Much less is
known in humans, where previous studies have been based solely
on uninfected lung tissue removed during cancer surgery or
non-living organ donations and limited to cross-sectional analysis
of resting T cells22,23. These estimates of frequency showed
that Trm cells are abundant in the lung where, at rest, inﬂuenza-
speciﬁc CD8þ Trm cells are more frequent than those for
cytomegalovirus. Our longitudinal analyses advance these
ﬁndings by showing in vivo how Trm cells in the human
airway arise following viral infection and how they relate to
disease severity. During acute infection, RSV-speciﬁc CD8þ Trm
cells were transiently joined by a CD103þCD69 population
that could represent a population that migrate from blood to
airway, although the ontogeny of Trm cells has yet to be fully
elucidated36,37. Interestingly, this may be the reverse of CD8þ
Trm cells generated against herpes simplex virus 1 (HSV-1) in
murine skin, where sequential induction of ﬁrst CD69 and then
CD103 has been observed, suggesting the impact of tissue type,
pathogen and/or interspecies differences38.
RSV-speciﬁc Trm cells in the airway showed phenotypic
changes suggestive of advanced differentiation, with downregula-
tion of co-stimulatory markers, but also reduced expression of
cytotoxicity molecules. We therefore propose that the very high
Trm cell frequencies seen during early convalescence can confer
absolute protection against early symptomatic reinfection but
may be functionally regulated to prevent excessive damage to the
delicate lung architecture. Inﬂammatory changes seen in the
airway during convalescence may represent the effect of large
numbers of CD8þ Trm cells interacting with residual RSV
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Figure 9 | Pre-existing RSV-speciﬁc memory CD8þ Tcells in the airway correlate with reduced disease severity. RSV-speciﬁc CD8þ T-cell responses
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antigen, but these caused no symptoms in healthy adults. In
contrast, in murine systems where large numbers of RSV-speciﬁc
CD8þ T cells are present at the same time as high viral titres,
life-threatening immunopathology can occur39. In our study, it
was not deemed acceptable to subject volunteers to a fourth
bronchoscopy to determine the longevity of Trm cells, while
other phenotypic and functional assessments were likely to be
qualitatively similar to the preinfection time point. Nevertheless,
it can be inferred that in these volunteers, CD8þ Trm
frequencies had waned signiﬁcantly, since the end of their last
natural RSV infection (though less precipitously than in blood).
This waning in the lung contrasts with long-lived Trm cells in
other tissues and may represent another mechanism by which
immunopathology is reduced40. Outstanding questions including
how Trm cells differentiate and the conditions required for
persistence remain major hurdles for generating protective
cell-mediated immunity in the mucosa. Both residual antigen
and cytokines such as TGF-b have been implicated in Trm cell
maintenance. Blockade of antigen recognition in the lungs of
inﬂuenza-infected mice leads to loss of Trm cells, while TGF-b is
expressed in respiratory mucosa and in vitro can induce
upregulation of CD103 (ref. 41). This is supported by our
ﬁndings of persistent RSV antigen in the airway associated with
virus-speciﬁc CD8þ Trm cells even 28 days after inoculation.
While there was no apparent disease associated with high
frequencies of RSV-speciﬁc CD8þ Trm cells in our cohort,
damaging immunopathology caused by boosting them in other
age groups and settings remains a risk.
These data show that immune responses in blood can
fundamentally misrepresent those at the site of infection. Our
ex vivo analyses of the respiratory compartment show that
adaptive immunity against respiratory viruses comprises multiple
specialised and non-redundant protective mechanisms distinct in
time and spatial organization. In RSV, locally produced mucosal
IgA constitutes an initial barrier to virus entry but does not
signiﬁcantly modulate disease severity once the barrier is
breached9. When that occurs, CD8þ Trm cells provide early
recognition and virus elimination, thus reducing symptom
severity and viral load. Only after these does systemic
immunity act to prevent widespread disease. We therefore
propose that Trm cells represent one of several immune
mechanisms that should be harnessed together for optimal
vaccine-mediated protection.
Methods
Ethics statement. The study was approved by the UK National Ethics Service
London—Fulham (study numbers 10/H0711/94 and 11/LO/1826). Written
informed consent was obtained from all volunteers.
Study design. Healthy, non-smoking adults aged 18–55 years were recruited
between 2012 and 2013. All subjects were genotyped for HLA class-I loci using
sequence-based typing. A total of 49 subjects were inoculated with 104 plaque-
forming units of RSV Memphis 37 (Meridian Lifesciences, Memphis, USA).
Following the challenge, participants were quarantined for 10 days. Cold symptoms
were assessed using symptoms diaries completed daily by participants. Reported
symptoms with a score of 0 (absent), 2 (moderate) or 3 (severe) included
sneezing, nasal discharge, nasal obstruction or sore throat (upper respiratory tract),
headache, malaise, fever (systemic) and cough, wheeze, shortness of breath
(lower respiratory tract symptoms). Cold was conﬁrmed if two out of the following
three conditions were fulﬁlled: nasal discharge lastingZ3 days, subjective feeling of
cold reported or cumulative 14-day symptom score Z14. Blood samples were
obtained at baseline and time points post inoculation as indicated in the text. Nasal
lavage samples were collected daily and used for viral load quantiﬁcation by qPCR
as previously described9,42. Brieﬂy, total RNA was isolated using the QIAamp
Viral RNA kit (Qiagen) according to the manufacturer’s instructions. Reverse
transcription of 13ml of total isolated RNA was achieved using the High Capacity
RNA-to-cDNA kit (Applied Biosystems) according to the manufacturer’s
instructions. qPCR with reverse trancription reactions for RSV N gene were
achieved using primers shown in Supplementary Table 7 and the TaqMan
Universal Master Mix II (Applied Biosystems) and 7500 Fast Real-Time PCR
System (Applied Biosystems). Absolute quantiﬁcation was calculated using a
plasmid DNA standard curve. As shown previously, infection status as determined
by qPCR positivity accorded 100% with multiplex qualitative PCR and plaque
assay. Bronchoscopists were blinded to the infection status of the volunteers.
Bronchoscopies were undertaken at 14 days before inoculation and 7 or 10 days
and 28 days post infection. Macroscopic appearance of the airways was reported as
‘normal’, ‘erythematous’ or ‘erythematous with contact bleeding’. Bronchial
brushings and biopsies were obtained at each time point. Bronchial epithelial cells
were washed with RPMI/10% fetal calf serum (FCS; R10) and stored in TRIzol
reagent (Invitrogen, Grand Island, USA) for viral load quantiﬁcation. BAL was
obtained by instillation of up to 120ml of normal saline, ﬁltered and centrifuged
before ﬂow cytometric analysis.
Immunohistochemistry. Endobronchial biopsies were ﬁxed immediately in 4%
paraformaldehyde and parafﬁn embedded. RSV was stained using polyvalent
mouse anti-RSV antibody (NCL-RSV3, Leica Biosystems, UK) at 1:50 dilution.
CD8þ T cells were identiﬁed by staining with mouse anti-CD8 (M0707, Dako) at
1:100 dilution using the EnVision peroxidase staining method (Dako, Denmark) as
previously described30. Brieﬂy, 5-mm sections were stained according to the
manufacturer’s instructions and an irrelevant mouse IgG1 kappa antibody
(MOPC21) was used as negative control for staining speciﬁcity of mouse
monoclonal antibodies. RSV-infected A549 cells were used as positive staining
controls. Quantiﬁcation was achieved as previously described with operators
blinded to sample timing and infection status30. Brieﬂy, slides were coded to avoid
observer bias and areas of epithelium and subepithelium assessed using a Leitz
Dialux 20 light microscope, Apple Macintosh computer and Image 1.5 software.
Total epithelial and subepithelial areas of two to three bronchial biopsies were
counted for each bronchoscopy. Cell counts were expressed as the number of cut
cell proﬁles with visible nucleus per mm2 of subepithelium and per 0.1mm2 of
epithlium. The coefﬁcient of variation for repeat counts of positive cells by a single
observer ranged from 5 to 6%.
PBMC isolation. PBMC isolation was performed by density centrifugation
using Histopaque 1077 (Sigma Aldrich, USA) according to the manufacturer’s
protocol. Cells were either used immediately or cryopreserved in FCS (Gibco
Life Technologies, USA) with 10% dimethyl sulfoxide (DMSO) in liquid nitrogen
for future assays.
Ex vivo interferon-c ELISpot assay. T-cell epitope mapping was performed by
INF-g ELISpot using 2 105 PBMCs in triplicate stimulated with peptide pools
(10 mgml 1 of each peptide) for initial screening followed by deconvolution with
single peptides (10 mgml 1). Plates were incubated for Z17 h at 37 C and
subsequently developed (Mabtech, Sweden). SFU were counted using AID ELISpot
software (Autoimmun Diagnostika GmbH, Germany) and analysed with positive
wells containing Z20 spots per 106 cells and a P value of r0.05 using a Student’s
t-test in at least two experiments.
Flow cytometry. HLA class-I (A*01:01 and B*07:02) tetramers were a gift from
Raﬁ Ahmed (Emory University, Atlanta, USA). Custom-made dextramers
(A*02:01) were purchased from Immudex (Copenhagen, Denmark). Whole blood
or BAL cell samples were stained by adding 2 ml of tetramer and incubating for
10min at room temperature before staining with surface antibodies for 20min.
Dextramer staining was performed in the same way on freshly isolated PBMCs or
BAL cells. Surface staining of whole blood was followed by erythrocytes lysis with
BD Lysis buffer. Cells were then ﬁxed with 1% paraformaldehyde solution or
prepared for intracellular staining by ﬁxing and permeabilization with BD
Fixation/Permeabilization kit. The following surface antibodies (including clone
and catalogue number) were used in the study: CD3 PE-CF594 (UCHT1,
BD#562280), CD4 APC-H7 (SK3, BD#641398), CD38 PE Cy7 (HB7, BD#335825),
Ki-67 FITC (B56, BD#556026), Perforin FITC (dG9, BD#556577), Granzyme B
V450 (GB11, BD#561151), CD45RA FITC (HI100, BD#555488), CCR7 PE
(150503, BD#560765), CD27 V450 (M-T271, BD#560448), CD28 PE Cy7 (CD28.2,
BD#560684), CCR5 V450 (2D7/CCR5, BD#562121), CD62L PE (DREG-56,
BD#555544; all BD Biosciences); CD8 PerCP Cy 5.5 (RPA-T8, #45-0088-42), CD69
FITC (FN50, 11-0699-42) and CD103 PE Cy7 (B-Ly7, #25-1038-42; all
eBioscience). Dilutions at which antibodies were used are shown in Supplementary
Table 8. FlowJo software (FlowJo LLC, USA) was used for data analysis.
In vitro peptide stimulation and intracellular cytokine staining. Intracellular
cytokine staining was used to conﬁrm epitopes identiﬁed by ELISpot. Thawed
PBMCs were rested overnight and stimulated the next day for 6 h in culture
medium (RPMI 1640, 10% FCS, 2mM glutamine, 100 IUml 1 penicillin/
streptomycin) using selected peptides (10 mgml 1) plus anti-CD28 and anti-
CD49. After 2 h, Brefeldin A (1 ml/ml) was added and after 6 h cells were washed
and stained with live/dead marker (Invitrogen, USA); IFN-g APC (B27, #554702),
TNF PE Cy7 (MAb11, #557647), interleukin-2 FITC (5344.111, #340448; all BD
Biosciences); and relevant surface markers. Dilutions at which antibodies were used
are shown in Supplementary Table 8. The frequencies of expression proﬁles for
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single, double and triple cytokine producers were calculated using the Boolean
combination gating option in FlowJo software (FlowJo LLC, USA).
RSV Memphis 37 sequence translation and in silico epitope prediction. The
genomic sequence of RSV Memphis 37 was translated into proteins from all six
possible open-reading frames and the resulting amino-acid sequences compared
against 11 RSV reference protein sequences obtained from RefSeq using blastx.
Hits were ﬁltered by removing those with an e-value lower than 1 10 6. These
were then veriﬁed by manual inspection. The capacity of all 9- and 10-mer peptides
derived from RSV M37 to bind HLA-A*01:01, A*02:01 and B*07:02 was predicted
with the Stabilized Matrix Method using the command-line version of the Immune
Epitope Database consensus prediction tool26. Peptides were selected if they scored
in the top 1% of predictions for each length or if they were the top two peptides for
the protein (to ensure even small proteins were represented for each allele).
Peptides were synthesized by A&A Labs LLC (San Diego, CA, USA) as crude
material, and resuspended at 20mgml 1 in 100% DMSO (v/v).
MHC peptide-binding assays. Quantitative measurements of peptide binding
to HLA class-I molecules were made by inhibition of binding of radiolabelled
standard peptides. MHC molecules were puriﬁed by afﬁnity chromatography
from the Epstein–Barr virus-transformed homozygous cell line JY, and assays
performed, as described previously43. Brieﬂy, peptides were tested at six different
concentrations covering a 100,000-fold dose range in three or more independent
assays. Lyophilized test peptides were solubilized in water, PBS (pH 7.2) or 100%
DMSO and serially diluted in 0.05% (v/v) NP-40/PBS. Each peptide dose (5 ml) was
loaded into the reaction vessel (Costar 96-well polypropylene round-bottom plate).
For positive (no peptide) and negative (no MHC) controls, wells were loaded with
NP-40/PBS alone. The MHC/labelled peptide reaction mix was prepared with PBS,
puriﬁed MHC of the desired allele, protease inhibitor cocktail, b2 microglobulin
and radiolabelled peptide. Reaction mix (10 ml) was added to all but the negative
control well and the plate sealed and incubated for 2 days in the dark at room
temperature. The concentration of peptide yielding 50% inhibition of the binding
of the radiolabelled probe peptide (half-maximal inhibitory concentration (IC50))
was calculated. Under the conditions used, where [radiolabelled probe]o[MHC]
and IC50Z[MHC], the measured IC50 values are reasonable approximations of the
true Kd values44,45.
Statistical analysis. On the basis of published data25, we calculated that a
minimum sample size of 16 in each arm (infected versus uninfected) would be
sufﬁcient to ﬁnd a difference of 1.3% of epitope-speciﬁc CD8þ T cells with 80%
power using a two-sided unpaired t-test with 5% signiﬁcance level (where the
variability in each group was 1.4%). Samples were only excluded where insufﬁcient
cells or material remained. Statistical analysis was performed using Graphpad
Prism and R software.
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